ArticleBiologia futura2021
Protective effect of hesperidin in Poloxamer-407 induced hyperlipidemic experimental rats.
Article in Biologia futura, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Inhibitory effect of trans-tiliroside on very low-density lipoprotein secretion in HepG2 cells and mouse liver.Journal of natural medicines · 2024Article
- Optimized Sugar-Free Citrus Lemon Juice Fermentation Efficiency and the Lipid-Lowering Effects of the Fermented Juice.Nutrients · 2023Article
- Beneficial effects of flavonoids on animal models of atherosclerosis: A systematic review and meta-analysis.iScience · 2023Article
- The Palliative and Antioxidant Effects of Hesperidin against Lead-Acetate-Induced Testicular Injury in Male Wistar Rats.Biomedicines · 2023Article
- Screening of Active Ingredients from Wendan Decoction in Alleviating Palmitic Acid-Induced Endothelial Cell Injury.Molecules (Basel, Switzerland) · 2023Article
- Lycopene Modulates Oxidative Stress and Inflammation in Hypercholesterolemic Rats.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The new exploration of pure total flavonoids extracted fromFrontiers in nutrition · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hyperlipidemia is one of the leading causes of, atherosclerosis, and cardiovascular disease. In this study, we evaluated the protective role of hesperidin (HES) against lipidemic stress in a hyperlipidemic model of rats. We developed a hyperlipidemic model of the rat through an i.p dose of poloxamer-407, 0.5 g/kg body weight for 3 alternative days in a week for 30 days and rats were supplemented with HES orally (100 mg/kg body weight) once daily. Bodyweight, fasting glucose, insulin, HOMA-IR index, triglyceride, cholesterol, ROS, FRAP, GSH, PMRS, AGE, MDA, PCO, AOPP, PON-1, TNF-α and IL-6, SGPT and SGOT were estimated in blood and plasma, and histopathology was done in liver tissue. Our data show that oxidative stress, inflammatory markers were increased in the P-407 treated group. Liver tissue histology also changes in the hyperlipidemic groups of rats.HES supplementation protects against P-407 induced alterations and maintains the redox homeostasis. Our results provide evidence that HES protects against lipidemic stress and redox imbalance induced by P-407 in rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.